Participated · Seed · Feb 2026

Entirety Biomedical is a Michigan-based medical device startup creating absorbable metal implants that offer titanium-like strength during healing and then safely resorb once bone union is achieved. Its patented Curasorb alloy underpins plate-and-screw and headless compression screw systems aimed initially at lower-extremity and maxillofacial procedures, allowing surgeons to avoid permanent hardware without changing existing surgical workflows or reimbursement models. The company completed its first preclinical study in 2024 and is running three additional preclinical studies, with early data showing strong osseointegration. These studies will guide a planned first-in-human clinical trial of its lower-extremity headless compression screw system. Entirety works closely with surgeons and strategic partners to identify unmet fixation needs and translate them into products that improve patient outcomes and reduce secondary removal surgeries. Founded by materials-science engineers Jake Edick and Carolyn Woldring, the team brings more than a decade of absorbable magnesium R&D experience and multiple related patents. The startup recently secured $1.2 million in seed funding to advance product development toward clinical trials.

Participated · Series B · Aug 2023

Astrocyte Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company based in Groton, Conn., focused on developing novel cerebroprotective therapeutics. Its lead candidate, AST-004, has shown efficacy across diverse small and large animal brain injury models and is being evaluated for a broad array of acute brain injuries including stroke and traumatic brain injury. Astrocyte is currently conducting Phase 1B clinical safety studies of AST-004 and is preparing for Phase 2 efficacy studies in 2024. The company is also assessing AST-004 in preclinical models of Alzheimer's disease to explore potential benefits in chronic neurodegenerative conditions. The announced financing will be used to accelerate clinical development of AST-004 and further preclinical assessment in Alzheimer's disease. Astrocyte positions its approach as a potential way to reduce astrocyte-induced excess inflammation and provide neuroprotection in combination and precision medicine strategies. Astrocyte Pharmaceuticals is advancing novel neuroprotective therapeutics intended to reduce brain injury from stroke, traumatic brain injury, concussion and other neurodegenerative conditions. Its lead therapeutic is based on technology licensed from the University of Texas Health Science Center at San Antonio. The company completed a Series A financing that raised $6 million. Proceeds from the round will be used to advance the lead program into Phase 1 human trials. Astrocyte describes itself as focused on addressing an unmet need for drugs that limit neurodegenerative brain injury. No operating metrics were disclosed in the article. Astrocyte Pharmaceuticals is a privately held drug development company focused on small‑molecule neuroprotective therapeutics for stroke, traumatic brain injury/concussion, and neurodegenerative disorders. The company is committed to proving the neuroprotective benefits of enhancing astrocyte function and advancing related therapeutic agents. Its lead program is AST‑004, which the company and investors cite as having promising preclinical efficacy and a novel mechanism of action. Astrocyte completed a Pre‑A financing that raised over $2.3M to support its development plans. The company intends to use proceeds to advance its first program into clinical studies. The press release also notes research support from the National Institute of Neurological Disorders and Stroke (NIH) and the Department of Defense under specific award numbers.

Participated · Seed · Aug 2018

Capillary Biomedical, headquartered in Irvine, California, develops the SteadiSet infusion set powered by its SteadiFlow technology to simplify and improve insulin pump therapy for people with Type 1 diabetes. The SteadiFlow platform features a soft, flexible cannula with multiple holes to reduce kinking, tissue damage, and inflammation, plus an integrated one-handed inserter. The SteadiSet is designed with materials selected for insulin stability and an adhesive optimized for extended wear to increase comfort, reliability, and predictability of insulin absorption. CapBio is pursuing extended-wear use of infusion sets for seven days and beyond and is conducting clinical studies to validate that performance. The company’s core cannula technology was developed with Professor Jeffrey Joseph and supported by the NIH and the JDRF T1D Fund. CapBio has previously raised over $10 million from organized angel investment groups and is advancing clinical trials to support broader adoption. Capillary Biomedical is developing the SteadiSet infusion set featuring SteadiFlow technology, a patented helical cannula design and a patent-pending helical inserter intended to reduce infusion set failures and insulin absorption variability. The company says the design is kink‑proof and combines advantages of steel needles and Teflon cannulas to improve comfort and reliability for pump users. Research specific to SteadiFlow was presented at the American Diabetes Association Scientific Sessions, and the core cannula work was developed at the Jefferson Artificial Pancreas Center with NIH and JDRF grant support. CapBio has assembled a veteran diabetes‑technology team, developed a minimal viable product, and filed multiple patent applications. Headquarters are in Irvine, California. The company plans clinical studies to support an initial 510(k) filing and preparation for a commercial launch in 2019; funds from the recent financing will support those activities.

Participated · Series A · Apr 2017

Sentien Biotechnologies is a clinical-stage company developing novel cell therapy approaches centered on its lead product, SBI-101. SBI-101 combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device to allow controlled, sustained delivery of MSC secreted factors. The product is being tested to treat systemic inflammatory diseases and is being developed specifically for acute kidney injury (AKI). The company will use the funds from its recent financing to support the initial clinical development of SBI-101. Sentien is led by CEO Brian Miller and is based in Cambridge, MA. The company recently completed a Series A to advance its clinical program. Sentien Biotechnologies is a preclinical regenerative medicine company led by CEO Brian Miller focused on cell-based therapies for critical care. Its lead product, the Sentinel™, is a cell-containing dialysis device being developed to treat severe Acute Kidney Injury (AKI). The company intends to use the recently raised Series A funds to conduct a planned Phase I study of Sentinel. Sentien has received multiple SBIR awards from the U.S. National Institutes of Health, including a $3M Phase IIB grant to advance the technology into a Phase I clinical trial. In conjunction with the financing, two investor representatives will join Sentien’s board. The company is based in Medford, Massachusetts.

Participated · Series B · Jul 2014

Siamab Therapeutics (formerly Sialix) has refocused on developing monoclonal antibodies to hinder tumor growth and advance cancer immunotherapy. The company targets tumor-associated carbohydrate antigens (TACAs), abnormal glycans on cancer cell surfaces, and says it has identified highly specific antibodies that can kill tumor cells and inhibit progression. Its technology was licensed from glycobiology researcher Ajit Varki at the University of California, San Diego, and Siamab maintains corporate headquarters in Cambridge while doing lab work in San Diego. With the latest funding the company is developing in vivo data for its first program and building an IND-enabling data package, with the aim of entering the clinic in the next couple of years. Financially, Siamab completed a $6 million Series B that began last year, with an additional $2 million tranche announced recently largely from angel investors.